Objective: Little is known about the risk of anxiety in women during midlife and the menopausal transition. We examined anxiety as a cluster of four symptoms and determined the association between menopausal stage and high anxiety during 10 years of follow-up of 2,956 women of multiple race/ethnicities.
T he prevalence of anxiety symptoms in midlife women is substantial, with up to 51% of women aged 40 to 55 years reporting any tension/nervousness or irritability in the past 2 weeks 1 or at the moment 2 and with 25% reporting frequent irritability or nervousness. 3 Compared with premenopausal women, perimenopausal women have a greater risk for each symptom of anxiety. 3 However, studies have reported conflicting results concerning the extent to which the prevalence of anxiety symptoms varies during different stages of the menopausal transition, with some studies indicating no statistically significant differences by menopausal stage 4, 5 and with others finding that early or late perimenopausal women have significantly higher rates of anxiety symptoms than premenopausal women. 6, 7 Thus, whether the menopausal transition is a period of increased risk for anxiety is unclear.
The absence of consistent findings regarding associations between anxiety and menopause status is probably caused by the assessment of different symptoms, study designs, and populations studied. Anxiety is a general term that refers to varying symptoms characterizing different anxiety disorders such as panic disorder (eg, suddenly feeling fearful for no reason), social phobia (eg, fear of social or performance situations), or generalized anxiety (eg, excessive and uncontrollable worry, irritability). Such heterogeneity in anxiety symptoms and disorders is reflected in the literature, most of which include diverse measures of individual anxiety symptoms such as Birritability[ or Bfeelings of panic, [ 5, 8 making it difficult to compare studies and to draw conclusions.
Compared with depression, anxiety symptoms and disorders have generated far less attention in studies of midlife women despite the prevalence of anxiety and their association with distress, impaired quality of life, and vasomotor symptoms (VMS). Indeed, studies that focus on anxiety symptoms or syndromes usually focus on their association with VMS rather than on their association with menopause status. 9<12 Nevertheless, a greater understanding of the unique influence of the menopausal transition on the occurrence of anxiety symptoms and syndromes is important because anxiety is not only prevalent in community populations but is also a problem frequently reported to healthcare providers by midlife women. 13, 14 Analysis of cross-sectional baseline data from the Study of Women's Health Across the Nation (SWAN) 3 found that the odds of frequent (Q6 d in the past 2 wk) irritability (odds ratio [OR], 1.33) and nervousness (OR, 1.54), adjusted for multiple covariates, were significantly higher among early perimenopausal women than among premenopausal women. However, conclusions about the increased risk of anxiety associated with the menopausal transition based on these data are limited by the crosssectional design, lack of late perimenopausal and postmenopausal women in the sample, and assessment of individual symptoms.
Importantly, anxiety has been consistently and significantly associated with VMS (hot flashes/night sweats) in studies of the menopausal transition. 9, 15 Because VMS are highly prevalent during the transition, it is difficult to determine if VMS underlie an observed association between anxiety and menopausal stage. Thus, it is unclear whether the transition from premenopause to postmenopause is a time of increased risk for high anxiety, independent of VMS. If so, what are the characteristics of women at greatest risk?
An individual symptom, although potentially distressing or bothersome, is not informative of its underlying condition or disorder and may be one of the reasons that studies do not report consistent findings. Therefore, in the current report, we aimed to extend the research on anxiety in three ways: (1) by assessing anxiety as a cluster of four symptoms; (2) by determining the association between menopausal stage and high anxiety during 10 years of follow-up of 2,956 women enrolled in SWAN; and (3) by evaluating whether the risk for high anxiety is different between women with high anxiety at study entry and women without high anxiety at study entry. We used the new measure to test the hypothesis that a cluster of anxiety symptomsVspecifically irritability, tension/ nervousness, feeling fearful for no reason, and heart racing or poundingVwould be more likely to occur during or after the menopausal transition than before the menopausal transition, independent of demographic factors, psychosocial factors, health factors, and VMS.
METHODS

Participants and procedures
The current report is based on data collected from participants in SWAN, a longitudinal, multiethnic, seven-site, community-based study of menopause and aging among 3,302 premenopausal and early perimenopausal women enrolled at baseline. A description of SWAN has previously been published. 16 Briefly, approximately 450 white women and a sample of a predetermined minority group were recruited at each of seven clinical sites across the country in 1995-1997: Japanese in Los Angeles, CA (University of California Los Angeles); Chinese in Oakland, CA (University of California Davis); African Americans in the Detroit area (University of Michigan, Ann Arbor, MI), Chicago (Rush University, Chicago, IL), Pittsburgh (University of Pittsburgh, Pittsburgh, PA), and Boston (Massachusetts General Hospital, Boston, MA); and Hispanics in Newark, NJ (University of Medicine and Dentistry New Jersey and Einstein). Eligibility criteria for SWAN included the following: aged 42 to 52 years, with an intact uterus, have had at least one menstrual period in the previous 3 months, have not used reproductive hormones in the previous 3 months, and self-identified as one of the site's designated race/ethnic groups. Of the 3,302 participants, the current analyses included 2,956 women who had complete anxiety data at baseline and at least one subsequent annual visit. The New Jersey site did not complete in-person clinic visits after the sixth annual follow-up (completed by 25%) and resumed clinic visits on follow-up 12. Each site received Institutional Review Board approval of the study protocol. A written informed consent form was obtained from all study participants.
Participants were assessed at study entry (baseline) and annually through visit 10 with a common standardized protocol that consisted of detailed questions about medical, reproductive, and menstrual history; lifestyle and psychosocial factors; and physical and psychological symptoms. Measurements of height and weight were obtained using a common protocol. Interviewer-administered and self-administered study forms and materials were available in English, Spanish, Japanese, and Cantonese, and bilingual staff were used as appropriate. Translations were prepared for the study (initial translation, back translation, and reconciliation).
Measures
Assessment of anxiety
At each visit, women completed a symptom checklist consisting of 15 items similar to those used in numerous studies of menopause. Women were asked if they had experienced each of these symptoms in the previous 2 weeks and if so, how frequently: none (0), 1 to 5 days (1), 6 to 8 days (2), 9 to 13 days (3), and daily (4). The questionnaire includes four symptoms of anxiety: irritability, nervousness or tension, feeling fearful for no reason, and heart pounding or racing. Responses to the anxiety items were summed. Owing to a skewed distribution, the summed scores were dichotomized as high anxiety and low anxiety. Women with the top 20% of scores (ie, Q4) were identified as having high anxiety. The internal consistency for the four symptoms was good based on baseline assessment: a Cronbach > of 0.77 and the scores were highly correlated with the Generalized Anxiety Disorder-7 (GAD-7; Spearman r = 0.71), a seven-item measure of generalized anxiety that was completed at the same time (visit 12) as the four-item measure used in the current analyses. GAD-7 has been shown to be a reliable and valid measure of anxiety in the general population and in primary care. 17, 18 Furthermore, GAD-7 means (SDs) in the low-anxiety group and the high-anxiety group (2.21 [2.7] and 8.69 [5. 29], respectively; P G 0.0001) were statistically different, providing additional support for the validity of the cluster of symptoms.
Menopausal stage
Menopausal stage was based on menstrual bleeding patterns in the previous 12 months and categorized as follows: premenopausal (menstrual period in the past 3 mo with no change in regularity in the past 12 mo); early perimenopausal (menstrual period in the past 3 mo with change in regularity in the previous 12 mo); late perimenopausal (no menstrual period within the past 3 mo but some menstrual bleeding within the past 12 mo); and postmenopausal (no menstrual period within the past 12 mo). The classifications are similar to those recommended by the World Health Organization. 19 We also identified a separate group of women who were postmenopausal and using hormone therapy (HT). Data from nonpostmenopausal HT users were excluded from the visit at which HT was being used.
Covariates
Age, race/ethnicity, and education were obtained at baseline during screening for eligibility. All other variables were obtained at each follow-up examination. Women self-reported whether medication for nerves/depression was taken at least twice weekly in the month before interview, which was verified by examination of medication containers in the clinic or by participants reading labels to the interviewer over the telephone. HT use was reported at each visit. Perceived health was categorized into excellent (referent category), very good, good, or fair/poor. Body mass index (kg/m 2 ) was calculated from measurements of weight and height, which were obtained with a calibrated scale and a stadiometer. VMS (hot flashes/night sweats) were reported on the checklist described above. Frequent VMS were defined as VMS reported on six or more days in the previous 2 weeks. Exposure to upsetting life events in the past 12 months was determined by women's responses to a checklist of 18 possible life events that might have occurred. Women indicated whether the event occurred and, if so, how upsetting it was (not at all, somewhat upsetting, very upsetting). A very upsetting life event was dichotomized as at least one versus none.
Statistical analyses
The analytic sample consisted of 2,956 women for whom we had 23,532 person-years of observations during the 10 years of annual visits. We compared the baseline characteristics of women with and without high anxiety at baseline to identify factors that were significantly different between these groups. Longitudinal random-effects logistic regression models were used to examine the odds of having high anxiety for each menopausal stage (premenopause, early perimenopause, late perimenopause, natural postmenopause, and postmenopause with HT use) from study entry through visit 10. Women were censored at the visit when their menopausal stage was undetermined (premenopausal or perimenopausal and concurrent use of HT, which can cause bleeding), but their data were included in subsequent analyses once they ceased HT use and stage could be determined. Women who reported having undergone hysterectomy and/or oophorectomy were censored from that visit onward. The initial basic model included age, race/ethnicity, education, study site, and time since baseline (as a measure of increasing age) to examine the association of menopausal stage and anxiety without adjustment for other relevant covariates. Subsequently, based on a priori knowledge and the literature, covariates (including medication use for a Bnervous condition,[ number of medical conditions, perceived general health, difficulty paying for basics, and experiencing at least one very stressful event) were added to the basic model. In the final model, we added frequent VMS to the analysis to determine whether they explained the association between menopausal stage and high anxiety. The interaction of baseline anxiety and menopausal stage was added to the randomeffects logistic regression fully adjusted analyses to determine if the association between stage and anxiety symptoms from visits 1 through 10 varied by whether women had high anxiety at baseline. The same set of analyses was conducted in the two groups stratified by baseline anxiety status. Diagnostic plots and standard model fit analyses were conducted to verify model structure and assumptions. Analyses were performed with SAS version 9.3 (SAS Institute, Cary, NC).
RESULTS
The baseline characteristics of the participants are described in Table 1 , which shows that women with and without high anxiety at baseline differed significantly by demographics, menopausal stage and VMS, health factors, and life events. Specifically, women with high anxiety were more likely to be Hispanic and less likely to be Chinese or Japanese, to have high school education or less, to have difficulty paying for basics, to be early perimenopausal, and to report frequent VMS, worse health characteristics, and at least one very upsetting event in the previous year. Table 2 shows the number of observations during the 10 years of follow-up at each menopausal stage for all women and for those with and without high baseline anxiety. Overall, women had highanxiety symptoms (ie, score Q4 on the anxiety symptom cluster) at 15.6% of premenopausal visits, 20.7% of early perimenopausal visits, 20.2% of late perimenopausal visits, 18.1% of postmenopausal visits, and 15.5% of postmenopausal visits when using HT. Analyses stratified by baseline anxiety indicated that, among women with high anxiety at baseline, the percentage of visits with high anxiety linearly decreased from premenopause (71.4%) to postmenopause (30.0%), whereas among women with low anxiety at baseline, the percentage of visits with anxiety was higher during each stage (10.7%-13.5%) of the menopausal transition than it was during premenopause (4.4%) and peaked during late perimenopause.
Menopausal stage and anxiety
In the basic model for the entire sample (Table 3 , model A), menopausal stage was significantly associated with high anxiety during 10 years of follow-up, with each stage having significantly higher odds than the premenopausal stage (overall OR, 1.41-1.78; P G 0.0001). The odds of high-anxiety symptoms peaked in late perimenopause but remained ele-vated in postmenopause with and without HT use, compared with premenopause. The addition of health variables and stressors did not change the overall pattern of ORs or the significance level (P value) of menopause stage (except for postmenopausal HT users), although the ORs were attenuated (Table 3, model B) . With the addition of frequent VMS to the analysis, menopausal stage was no longer significant overall (Table 3 , model C). In contrast, women reporting frequent VMS had nearly triple the odds of anxiety compared with women reporting less frequent VMS, and African-American and Chinese women were significantly less likely than white women (31% and 39%, respectively) to have high-anxiety symptoms even after adjusting for VMS and other covariates.
To determine whether the impact of menopausal stage on high anxiety for 10 years differed between women with high baseline anxiety and women without high baseline anxiety, we added an interaction term of menopausal stage with the presence/absence of high baseline anxiety to the fully adjusted model for all women. Results showed that the interaction was significant at P = 0.001, indicating that the odds of high anxiety during and after the menopausal transition differed between women with high baseline anxiety and women without high baseline anxiety. Therefore, the final results are based on separate analyses of these groups as described below and are shown in Tables 4 and 5 .
Menopausal stage and anxiety in women without high baseline anxiety
All three models ( Table 4 , models A-C) for women without high baseline anxiety showed that menopausal stage was significantly associated with the odds of high anxiety (P G 0.05) irrespective of the addition of health-and stress-related factors (Table 4 , model B) and VMS (Table 4, model C). Specifically, among women with low anxiety at baseline compared with women with low anxiety at premenopause, the ORs for high anxiety were significantly greater when they were early perimenopausal (OR, 1.58) or late perimenopausal (OR, 1.61), postmenopausal (OR, 1.56), or postmenopausal and using HT (OR, 1.58), adjusted for health, stressor, and VMS variables. VMS were also significantly associated with high anxiety, with an OR of 2.43.
Menopausal stage and anxiety in women with high baseline anxiety
For women who had high anxiety at baseline, menopause stage was not significantly associated with high anxiety for 10 years in the basic model ( Table 5 , model C). In the basic model, ORs were elevated in later menopause stages by 20% to 44% but were not significantly different from premenopause. The addition of health, stressor, and VMS variables reduced the ORs to close to 1.0. In contrast, frequent VMS were significantly associated with high anxiety, with an OR of 3.56.
Covariates
As shown in Tables 4 and 5 , education and number of medical conditions were not associated with high anxiety in either the high baseline anxiety group or the low baseline anxiety group. Compared with excellent perceived health, fair/ poor perceived health increased the risk for high anxiety by 3.8 times in the baseline high-anxiety group and by 6.3 times in the baseline low-anxiety group, and an upsetting event more than doubled the odds of high anxiety in both groups. In the low baseline anxiety group, the odds of psychotropic drug use and having a hard time paying for basics were significantly associated with high anxiety during the study, and African-American and Chinese women had significantly lower odds of high anxiety than white women.
DISCUSSION
In a large sample of middle-aged women, we found that during 10 years of annual assessment, women who had low anxiety at baseline were significantly more likely to meet criteria for high-anxiety symptoms at perimenopause or postmenopause than at premenopause, independent of multiple risk factors, including upsetting life events, financial strain, fair/poor perceived health, and VMS. However, among women who started the study with high anxiety, menopausal stage was not associated with high anxiety whether or not VMS were included in the analyses. Among women with high baseline anxiety ( Table 2) , there was a linear reduction in the percentage of women with high anxiety across the menopausal stages (71.4%-30.0%), suggesting regression to the mean. Among women with low baseline anxiety, the percentage of those who had high anxiety peaked in late perimenopause (13.5%), decreased during postmenopause (12.7%), and was significantly higher than in premenopause (4.4%), suggesting that this may be caused by the effect of menopausal stage rather than regression to the mean. To our knowledge, no other study has examined the risk of high anxiety in subgroups of women.
Results for the entire sample were consistent with studies showing that individual anxiety symptoms were more strongly related to VMS than to the menopausal transition. 5, 10 Other studies found that early or late perimenopausal women had significantly higher rates of anxiety symptoms than premenopausal women, 6,7 but these studies did not adjust for VMS. Of interest, the association of frequent VMS with high anxiety in the current study was significant for women with and without high anxiety at baseline, but the odds were greater among the former (3.56 vs 2.43). For those without baseline high anxiety, both VMS and menopausal stage significantly increased the odds of high anxiety.
Given the differential impact of the menopausal transition on the two groups of women studied, the women who entered the study with high anxiety may have had relatively chronic anxiety. We found that about 40% to 50% of these women had high anxiety at each annual visit, and about half had three or more visits with high anxiety. In contrast, among the women with low baseline anxiety, about 11% to 14% had high anxiety at each visit, and 11% had three or more visits with high anxiety. As shown in Table 1 and as noted above, the two groups of women were also different at baseline, with the lowanxiety women more likely to be Chinese or Japanese, to have better socioeconomic and health characteristics (including fewer women using psychotropic medications and fewer women reporting frequent VMS), and to have less exposure to stressful events in the previous year. Thus, it seems that the two groups of women may represent two different populations and that the menopausal transition may confer vulnerability to anxiety in women who are not typically anxious. Perhaps women who are more often anxious may be somewhat habituated to anxious feelings and less susceptible to perturbations of neuroactive steroids during the menopausal transition; other factors may override the effect of the transition; or there may be a ceiling effect due to measurement of anxiety such that women with high baseline anxiety cannot become more anxious.
The current study has a number of strengths. To our knowledge, no other study has examined the risk of anxiety symptoms or syndromes during the menopausal transition separately for women who initially did have high-anxiety symptoms and women who initially did not have high-anxiety symptoms. We had 10 years of follow-up data available to evaluate changes in risk for high anxiety as women transitioned through the stages of menopause, independent of multiple menopausal, psychosocial, and health factors that varied over time and were independently associated with anxiety. Rather than using individual symptoms as anxiety outcome, we used a cluster of anxiety symptoms that was highly correlated with a standard measure of generalized anxiety disorder.
Study limitations should be considered when interpreting the results of this study. We did not have data on the history of anxiety symptoms before study entry among the women who entered SWAN without anxiety. It is possible that they experienced such symptoms in the past and happened not to have them at baseline assessment. However, the baseline characteristics of women with and without anxiety symptoms were significantly different, suggesting that those without symptoms represented a population different from those with symptoms. Because the varying anxiety symptoms and full diagnostic criteria that define different anxiety disorders are not included in our measure of anxiety, caution should be taken in extrapolating the results to anxiety disorders themselves.
CONCLUSIONS
For a subset of women with low anxiety premenopausally, the risk for high anxiety is greater during or after the menopausal transition than before the menopausal transition, independent of frequent VMS and other established risk factors. However, among women with premenopausal anxiety, the risk for high anxiety remains high, irrespective of the menopausal transition and frequent VMS, with which it is consistently associated. The identification of a subgroup of women for whom the transition poses an increased risk of high anxiety points to the need for further research to determine the specific aspects of the transition that confer such vulnerability, the extent to which anxiety persists, and the history and circumstances of women who develop high anxiety. Additional research on midlife women who report high anxiety premenopausally is also warranted. The findings also have implications for clinicians, suggesting that it is useful for healthcare providers to obtain information from women presenting with high anxiety about its onset and duration, as well as about bleeding patterns and VMS. Women with anxiety may benefit from treatment of the anxiety or referral to a mental health practitioner.
